Getinge AB (Getinge AB) Total Liabilities : $2,278 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Getinge AB Total Liabilities?

Getinge AB's Total Liabilities for the quarter that ended in Mar. 2024 was $2,278 Mil.

Getinge AB's quarterly Total Liabilities increased from Sep. 2023 ($1,941.76 Mil) to Dec. 2023 ($2,260.08 Mil) and increased from Dec. 2023 ($2,260.08 Mil) to Mar. 2024 ($2,278.01 Mil).

Getinge AB's annual Total Liabilities declined from Dec. 2021 ($2,132.00 Mil) to Dec. 2022 ($2,079.30 Mil) but then increased from Dec. 2022 ($2,079.30 Mil) to Dec. 2023 ($2,260.08 Mil).

Getinge AB Total Liabilities Historical Data

The historical data trend for Getinge AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Getinge AB Total Liabilities Chart

Getinge AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

2,516.86

2,813.31

2,132.00

2,079.30

2,260.08

Getinge AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															1,902.10	1,999.89	1,941.76	2,260.08	2,278.01

Getinge AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Getinge AB's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1285.388	+	(483.544	+	219.739
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	271.409)
	=	2,260

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	5224.029	-	2963.949
	=	2,260

Getinge AB's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	984.411	+	(800.188	+	236.475
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	256.932)
	=	2,278

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	5409.507	-	3131.501
	=	2,278

Getinge AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of Getinge AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Getinge AB (Getinge AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Getinge AB (OTCPK:GNGBF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

GNGBY:USA GETI B:Sweden GETIBs:UK 0GZV:UK GTN:Germany

Address

Lindholmspiren 7A, P.O. Box 8861, Gothenburg, SWE, SE-417 56

Website

https://www.getinge.com

Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in the hospital, pharmaceutical, and research settings. The company reports in three segments: acute care therapies (54% of revenue), surgical workflows (32%), and life sciences (14%). Product areas include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems. Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales (U.S. 33% of sales), Asia-Pacific 25%, and Europe, Middle East, and Africa the remaining 30%.